Document is current
Any future updates will be listed below
-
Authors
Swillens, Julie E. M. https://orcid.org/0000-0001-9337-1318
Nagtegaal, Iris D. https://orcid.org/0000-0003-0887-4127
Engels, Sam
Lugli, Alessandro https://orcid.org/0000-0002-9264-5185
Hermens, Rosella P. M. G.
van der Laak, Jeroen A. W. M. https://orcid.org/0000-0001-7982-0754
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (945358, 945358, 945358, 945358, 945358)
KWF Kankerbestrijding (2017-10602, 2017-10602, 2017-10602, 2017-10602, 2017-10602)
- License Information
-
More Information
Article History
Received: 17 November 2022
Accepted: 26 July 2023
First Online: 16 August 2023
Competing interests
: The authors Julie Swillens, Iris Nagtegaal, Sam Engels, Alessandro Lugli and Rosella Hermens have no competing non-financial or financial interests to declare. Jeroen van der Laak has competing financial interests: He is a member of the advisory boards of Philips, the Netherlands and ContextVision, Sweden, and received research funding from Philips, the Netherlands, ContextVision, Sweden, and Sectra, Sweden in the last five years. He is chief scientific officer (CSO) and shareholder of Aiosyn BV, the Netherlands.
